Clinical Trends for July 2018

Ryan Syrek


July 27, 2018

Trending Clinical Topic of the Week (July 7-13): Hyperhidrosis

Approval of a new product designed to help with a sometimes debilitating condition resulted in this week's top search term. The US Food and Drug Administration has approved topical glycopyrronium (Qbrexza) for the treatment of primary axillary hyperhidrosis. Hyperhidrosis is a condition characterized by excessive sweating that can impede normal daily activities, resulting in psychological, social, and physical impairment. Although hyperhidrosis may affect various regions of the body and may be idiopathic or secondary to other diseases, metabolic disorders, febrile illnesses, or medication use, the new treatment option is thus far indicated only for the primary axillary form of the condition. Qbrexza is a topical anticholinergic cloth that is applied to the underarms, resulting in a noticeable and sustained decrease in overall sweat production. The FDA has approved use in adults and children as young as 9 years. Prescribing information is available online. This week's trending clinical topic is undoubtedly associated with welcome news for patients and those caring for them.

For more information on hyperhidrosis, read here.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.